Failure of HIV-2 viral load assay in a severely immunodeficient patient: Clinical and therapeutic management issues

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 100, Issue 3, 2006, Pages 282-284

  Fonquernie, Laurent ^a   Eholié, Serge P ^a   Damond, Florence ^b   Lacombe, Karine ^a   Girard, Pierre Marie ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Highly active antiretroviral therapy; HIV 2; Quantitative plasma HIV 2 RNA

Indexed keywords

ABACAVIR; AMPRENAVIR; COLONY STIMULATING FACTOR 1; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; TREATMENT FAILURE; VIRUS LOAD; VIRUS STRAIN;

ADULT; ANTI-HIV AGENTS; HIV INFECTIONS; HIV-2; HUMANS; MALE; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 2; RNA VIRUSES;

EID: 30744477704     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trstmh.2005.08.007     Document Type: Article

References (11)

1. C.A. Adjé-Touré R. Cheingsong J.G. Garcia-Lerma S. Eholié M.Y. Borget J.M. Bouchez R.A. Otten C. Maurice M. Sassan-Morokro R.E. Ekpini M. Nolan T. Chorba W. Heneine J.N. Nkengasong Antiretroviral therapy in HIV-2 infected patients: Changes in plasma viral load, CD4+ cell counts and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire AIDS 17 Suppl. 3 2003 S49-S54
2. F. Damond C. Apetrei D. Descamps F. Brun-Vezinet F. Simon HIV-1 subtypes and plasma RNA quantification AIDS 13 1999 286-287
3. F. Damond M. Gueudin S. Pueyo I. Farfara D.L. Robertson D. Descamps G. Chene S. Matheron P. Campa F. Brun-Vezinet F. Simon Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections J. Clin. Microbiol. 40 2002 3654-3659
4. J.F. Delfraissy Prise en charge thérapeutique des personnes infectées par le VIH Recommandations du Groupe d'Experts. Rapport 2002 2002 Flammarion Medecine Sciences Paris 219-220
5. EACS (European Guidelines Group) European guidelines for the clinical management of treatment of HIV infected adults in Europe AIDS 17 Suppl. 2 2003 S3-S26
6. S. Matheron S. Pueyo F. Damond F. Simon A. Leprêtre A. Campa R. Salomon G. Chene F. Brun-Vezinet Factors associated with clinical progression in HIV-2 infected patients: The French ANRS Cohort AIDS 17 2003 2593-2601
7. N.T. Parkin J.M. Schapiro Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV Antivir. Ther. 9 2004 3-12
8. D. Pienazek D. Ellenberger L.M. Janini A.C. Ramos J.N. Nkengasong M. Sassan-Morokro D.J. Hu I.M. Coulibally E. Ekpini C. Bandea A. Tanuri A.E. Greenberg S.Z. Wiktor M.A. Rayfield Predominance of human immunodeficiency virus type 2 subtype B in Abidjan, Ivory Coast AIDS Res. Hum. Retroviruses 180 1999 1116-1121
9. N.A. Smith T. Shaw N. Berry C. Vella L. Okorafor D. Taylor J. Ainsworth A. Choudhury R.S. Daniels S. El Gadi A. Fakoya G. Moyle J. Oxford R. Tedder S. O'Shea A. de Ruiter J. Breuer Antiretroviral therapy in HIV-2 infected patients J. Infect. 42 2001 126-133
10. M. Van der Ende J.M. Prins K. Brinkman M. Kenter J. Veenstra S.V. Danner H.G. Niesters A.D. Osterhaus M. Shutten Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2 infected patients AIDS 17 Suppl. 3 2003 S55-S61
11. M. Witvrouw C. Pannecouque W.M. Switzer T. Folks E. De Clercq W. Heneine Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis Antivir. Ther. 9 2004 57-65